| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30022203 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022204 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022205 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022206 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022207 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022208 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022209 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022210 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022211 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
| TVIS30022212 | HIV | ENSG00000198793.14 | protein_coding | MTOR | Yes | No | 2475 | P42345 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MTOR |
|---|---|
| DrugBank ID | DB01590 |
| Drug Name | Everolimus |
| Target ID | BE0002386 |
| UniProt ID | P42345 |
| Regulation Type | inhibitor |
| PubMed IDs | 18466433; 20155724; 19774211; 19344392; 20569080; 20531964; 11752352 |
| Citations | Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM: Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x.@@Rostaing L, Kamar N: mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol. 2010 Mar-Apr;23(2):133-42.@@George S, Bukowski RM: Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15.@@Teachey DT, Grupp SA, Brown VI: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16.@@Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E: New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121.@@Coppin C: Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics. 2010 May 25;4:91-101.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved |
| Direct Classification | Macrolide lactams |
| SMILES | [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C(C)[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC |
| Pathways | |
| PharmGKB | PA164746311 |
| ChEMBL | CHEMBL1908360 |
